サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：ヒト胚性幹細胞の2030年までの市場予測： タイプ別、供給源別、用途別、地域別の世界分析
市場調査レポート
商品コード
1371999

ヒト胚性幹細胞の2030年までの市場予測： タイプ別、供給源別、用途別、地域別の世界分析

Human Embryonic Stem Cells Market Forecasts to 2030 - Global Analysis By Type (Totipotent Stem Cells, Pluripotent Stem Cells, Multipotent Stem Cells, Oligopotent Stem Cells, Unipotent Stem Cells and Other Types), Source, Application and By Geography

出版日
ページ情報
英文 200+ Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.82円
ヒト胚性幹細胞の2030年までの市場予測： タイプ別、供給源別、用途別、地域別の世界分析
出版日: 2023年10月01日
発行: Stratistics Market Research Consulting
ページ情報: 英文 200+ Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

Stratistics MRCによると、世界のヒト胚性幹細胞市場は2023年に18億米ドルを占め、予測期間中にCAGR 11.2％で成長し、2030年には38億米ドルに達する見込みです。

受精から通常5～7日後の胚盤胞期にあるヒト胚の内部細胞塊から、多能性幹細胞の一種であるヒト胚性幹細胞が生成されます。この細胞は、ヒトの体内のほとんどすべての細胞に成長することができます。ヒトの初期発生において重要な機能を果たすだけでなく、再生医療や研究に応用できる大きな可能性を秘めています。ヒト胚性幹細胞を用いた治療薬の有効性と安全性を確保するためには、それを製造し、展開するための厳格な品質管理手順と安全性評価が不可欠です。

2022年8月に発表されたDVCステムの記事によると、パーキンソン病に対する幹細胞治療の目標は、破壊された脳細胞を健康な未分化の幹細胞と置き換えることであることが確認されました。

高まる技術の進歩

ヒト胚性幹細胞の市場は、技術的進歩から大きな恩恵を受けています。これらの開発により、ヒト胚性幹細胞の有効性、安全性、有用性は大幅に改善され、研究や治療への応用の可能性において、より魅力的な選択肢となっています。研究者は、3次元（3D）培養モデルの開発により、ヒトの体内における細胞の自然な環境をより正確に再現できるようになっています。その結果、ヒト胚性幹細胞は、再生治療のための特定の細胞タイプへの分化が改善されました。CRISPR-Cas9のような技術革新の助けを借りて、hESCゲノムを正確に編集することができるようになり、遺伝子編集の分野に革命をもたらしています。したがって、上記のすべての要因が市場の成長を後押ししています。

胚性幹細胞使用の倫理性に関する懸念

胚性幹細胞（ESC）の治療可能性を探る研究は、ヒト胚の殺害を含む多くの道徳的ジレンマと関連しています。胚性幹細胞を用いた治療法の開発において何が支援されうるかを規定する適切な政府法の欠如は、最終的に市場の成長をある程度制限するかもしれないです。研究者、科学者、製薬会社が胚由来幹細胞による治療法を開発し、その商業化を加速できるよう、この分野の法律は複雑であるため、連邦法がさらに必要です。

慢性疾患の増加

糖尿病、心血管疾患、神経疾患、自己免疫疾患などの慢性疾患の罹患率が上昇しているため、効率的な治療法に対する需要が高まっています。これらの疾患は、永久的な組織損傷を含むことが多いが、ヒト胚性幹細胞を用いた治療法で治療できる可能性があります。組織の劣化や臓器の機能不全は慢性疾患患者に頻繁に見られ、再生医療技術は損傷した組織や臓器を修復、置換、再生するためにそれらを使用するため、慢性疾患の長期的影響に取り組むための有用な資源です。特定の慢性疾患に対するヒト胚性幹細胞を用いた治療の安全性と有効性を明らかにするため、臨床研究が開始されています。

免疫拒絶反応の傾向

免疫拒絶反応は、ヒト胚性幹細胞由来の細胞治療を失敗させる可能性があります。移植された細胞は、レシピエントの免疫系がそれを異質なものとして認識した場合、攻撃され死滅する可能性があり、治療が無意味なものとなり、ヒト胚性幹細胞を用いた治療の長期的な利点が制限される可能性があります。最初の生着が有効であったとしても、持続的な免疫反応によって移植細胞が徐々に消失し、治療効果の寿命が短くなるため、市場の成長を妨げる可能性があります。

COVID-19の影響

パンデミックは研究所の研究プロジェクト、特に幹細胞プロジェクトに支障をきたしました。ヒト胚性幹細胞の研究開発や臨床試験は、いくつかの研究機関の一時的な閉鎖や活動縮小によって妨げられました。さらに、研究施設の閉鎖、患者募集の課題、安全性の懸念などにより、これらの臨床試験の進捗は遅れ、医学研究や治療開発の安全性と有効性がより重要視されるようになっています。その結果、ヒト胚性幹細胞を用いた医薬品はより徹底的な安全性評価を受けることになり、市場成長の妨げとなる可能性があります。

予測期間中、全能性幹細胞分野が最大となる見込み

全能性幹細胞（totipotent stem cells）分野は、特殊な幹細胞であり、胚外組織や胚組織を含むヒトの体内のあらゆる種類の細胞がこれらの細胞から形成される可能性があるため、有利な成長が見込まれます。全能性幹細胞は、胚外組織を除くすべての体細胞に成長することができるという点で、全能性幹細胞とは異なります。全能性幹細胞がどのようにして異なる細胞種に成長するのかを理解することは、この細胞を用いた研究によって助けられます。

予測期間中、幹細胞生物学研究分野のCAGRが最も高くなると予想されます。

幹細胞生物学研究セグメントは、予測期間中にCAGRが最も高くなると予想されます。また、様々な種類の幹細胞が医療にも利用されています。最近、数多くのバイオ医薬品企業が、がんや神経疾患を含む様々な疾患に対して臨床段階で数多くの用途があるこれらの化合物について実質的な研究を実施しています。パーキンソン病やがんなどの疾患の頻度が高まっていることから、幹細胞生物学研究は今後さらに成長することが予想されます。このような理由から、調査対象市場は予測期間を通じて大幅な成長が見込まれています。

最大のシェアを占める地域

北米は、政府による創薬への重点化、ヘルスケアへの投資、創薬技術開発のための先進的なインフラ整備が進んでいることに加え、同地域の複数の企業による開発戦略の拡大により、予測期間中最大の市場シェアを占めると予測されます。さらに、投薬研究や関連臨床研究に対する厳しい規制規則が市場を活性化すると予測されています。米国では、バイオ医薬品メーカーが生物学的製剤やバイオ類似製剤を上市していることも、市場拡大を後押しすると予想される要因です。

CAGRが最も高い地域：

欧州は、ヒト胚性幹細胞を研究および治療の両方に使用することを規制する法律が厳格であるため、予測期間中に最も高いCAGRを示すと予測されます。幹細胞を用いた医薬品の創製や承認は、各国の規制機関や欧州医薬品庁（EMA）によって規制されています。例えば、欧州では、脊髄損傷、心臓病、変性疾患など、様々な疾患に対してヒト胚性幹細胞を用いた臨床研究が実施されており、また現在も実施中です。これらの臨床試験の目的は、幹細胞を用いた治療の有効性と安全性を評価することです。ヒト胚性幹細胞の研究を進め、実用化するために、この地域では学術機関、バイオテクノロジー企業、ヘルスケア施設間の提携が一般的であり、これが市場を後押ししています。

無料のカスタマイズサービス

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

  • 企業プロファイル
    • 追加市場プレイヤーの包括的プロファイリング（3社まで）
    • 主要企業のSWOT分析（3社まで）
  • 地域セグメンテーション
    • 顧客の関心に応じた主要国の市場推計・予測・CAGR（注：フィージビリティチェックによる）
  • 競合ベンチマーキング
    • 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

目次

第1章 エグゼクティブサマリー

第2章 序文

  • 概要
  • ステークホルダー
  • 調査範囲
  • 調査手法
    • データマイニング
    • データ分析
    • データ検証
    • 調査アプローチ
  • 調査ソース
    • 1次調査ソース
    • 2次調査ソース
    • 前提条件

第3章 市場動向分析

  • 促進要因
  • 抑制要因
  • 機会
  • 脅威
  • アプリケーション分析
  • 新興市場
  • 新型コロナウイルス感染症（COVID-19）の影響

第4章 ポーターのファイブフォース分析

  • 供給企業の交渉力
  • 買い手の交渉力
  • 代替品の脅威
  • 新規参入業者の脅威
  • 競争企業間の敵対関係

第5章 世界のヒト胚性幹細胞市場：種類別

  • 全能性幹細胞
  • 多能性幹細胞
  • 多分化能幹細胞
  • オリゴ能性幹細胞
  • 単能性幹細胞
  • その他のタイプ

第6章 世界のヒト胚性幹細胞市場：ソース別

  • 骨髄
  • 成人の身体組織
  • 胚組織
  • 胎児組織
  • 分化した体細胞
  • その他の情報源

第7章 世界のヒト胚性幹細胞市場：用途別

  • 幹細胞生物学の調査
  • 再生医療
  • ヒト組織工学
  • 毒性試験
  • 血液疾患の治療
  • 心血管疾患の治療
  • その他の用途

第8章 世界のヒト胚性幹細胞市場：地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • イタリア
    • フランス
    • スペイン
    • その他欧州
  • アジア太平洋地域
    • 日本
    • 中国
    • インド
    • オーストラリア
    • ニュージーランド
    • 韓国
    • その他アジア太平洋地域
  • 南米
    • アルゼンチン
    • ブラジル
    • チリ
    • その他南米
  • 中東とアフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • カタール
    • 南アフリカ
    • その他中東とアフリカ

第9章 主な発展

  • 契約、パートナーシップ、コラボレーション、合弁事業
  • 買収と合併
  • 新製品の発売
  • 事業拡大
  • その他の主要戦略

第10章 企業プロファイル

  • PeproTech Inc.
  • Astellas Pharma Inc.
  • Merck KGaA
  • Lineage Cell Therapeutics Inc.
  • PromoCell GmbH
  • Thermo Fisher Scientific
  • ViaCyte, Inc.
  • Takara Bio Inc.
  • STEMCELL Technologies Inc
  • Cell Cure Neurosciences LTD
  • CellGenix GmbH
  • ESI BIO
  • Lonza
  • Kite Pharma
  • Cynata
  • Sumanas, Inc.
  • LifeCell
  • International Stem Cell Corporation
  • Genea BioCells
  • Geron
図表

List of Tables

  • Table 1 Global Human Embryonic Stem Cells Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Human Embryonic Stem Cells Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Human Embryonic Stem Cells Market Outlook, By Totipotent Stem Cells (2021-2030) ($MN)
  • Table 4 Global Human Embryonic Stem Cells Market Outlook, By Pluripotent Stem Cells (2021-2030) ($MN)
  • Table 5 Global Human Embryonic Stem Cells Market Outlook, By Multipotent Stem Cells (2021-2030) ($MN)
  • Table 6 Global Human Embryonic Stem Cells Market Outlook, By Oligopotent Stem Cells (2021-2030) ($MN)
  • Table 7 Global Human Embryonic Stem Cells Market Outlook, By Unipotent Stem Cells (2021-2030) ($MN)
  • Table 8 Global Human Embryonic Stem Cells Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 9 Global Human Embryonic Stem Cells Market Outlook, By Source (2021-2030) ($MN)
  • Table 10 Global Human Embryonic Stem Cells Market Outlook, By Bone Marrow (2021-2030) ($MN)
  • Table 11 Global Human Embryonic Stem Cells Market Outlook, By Adult Body Tissues (2021-2030) ($MN)
  • Table 12 Global Human Embryonic Stem Cells Market Outlook, By Embryonic Tissues (2021-2030) ($MN)
  • Table 13 Global Human Embryonic Stem Cells Market Outlook, By Fetal tissues (2021-2030) ($MN)
  • Table 14 Global Human Embryonic Stem Cells Market Outlook, By Differentiated Somatic Cells (2021-2030) ($MN)
  • Table 15 Global Human Embryonic Stem Cells Market Outlook, By Other Sources (2021-2030) ($MN)
  • Table 16 Global Human Embryonic Stem Cells Market Outlook, By Application (2021-2030) ($MN)
  • Table 17 Global Human Embryonic Stem Cells Market Outlook, By Stem Cell Biology Research (2021-2030) ($MN)
  • Table 18 Global Human Embryonic Stem Cells Market Outlook, By Regenerative Medicine (2021-2030) ($MN)
  • Table 19 Global Human Embryonic Stem Cells Market Outlook, By Tissue Engineering (2021-2030) ($MN)
  • Table 20 Global Human Embryonic Stem Cells Market Outlook, By Toxicology Testing (2021-2030) ($MN)
  • Table 21 Global Human Embryonic Stem Cells Market Outlook, By Blood Disease Treatment (2021-2030) ($MN)
  • Table 22 Global Human Embryonic Stem Cells Market Outlook, By Treatment of Cardiovascular Disease (2021-2030) ($MN)
  • Table 23 Global Human Embryonic Stem Cells Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 24 North America Human Embryonic Stem Cells Market Outlook, By Country (2021-2030) ($MN)
  • Table 25 North America Human Embryonic Stem Cells Market Outlook, By Type (2021-2030) ($MN)
  • Table 26 North America Human Embryonic Stem Cells Market Outlook, By Totipotent Stem Cells (2021-2030) ($MN)
  • Table 27 North America Human Embryonic Stem Cells Market Outlook, By Pluripotent Stem Cells (2021-2030) ($MN)
  • Table 28 North America Human Embryonic Stem Cells Market Outlook, By Multipotent Stem Cells (2021-2030) ($MN)
  • Table 29 North America Human Embryonic Stem Cells Market Outlook, By Oligopotent Stem Cells (2021-2030) ($MN)
  • Table 30 North America Human Embryonic Stem Cells Market Outlook, By Unipotent Stem Cells (2021-2030) ($MN)
  • Table 31 North America Human Embryonic Stem Cells Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 32 North America Human Embryonic Stem Cells Market Outlook, By Source (2021-2030) ($MN)
  • Table 33 North America Human Embryonic Stem Cells Market Outlook, By Bone Marrow (2021-2030) ($MN)
  • Table 34 North America Human Embryonic Stem Cells Market Outlook, By Adult Body Tissues (2021-2030) ($MN)
  • Table 35 North America Human Embryonic Stem Cells Market Outlook, By Embryonic Tissues (2021-2030) ($MN)
  • Table 36 North America Human Embryonic Stem Cells Market Outlook, By Fetal tissues (2021-2030) ($MN)
  • Table 37 North America Human Embryonic Stem Cells Market Outlook, By Differentiated Somatic Cells (2021-2030) ($MN)
  • Table 38 North America Human Embryonic Stem Cells Market Outlook, By Other Sources (2021-2030) ($MN)
  • Table 39 North America Human Embryonic Stem Cells Market Outlook, By Application (2021-2030) ($MN)
  • Table 40 North America Human Embryonic Stem Cells Market Outlook, By Stem Cell Biology Research (2021-2030) ($MN)
  • Table 41 North America Human Embryonic Stem Cells Market Outlook, By Regenerative Medicine (2021-2030) ($MN)
  • Table 42 North America Human Embryonic Stem Cells Market Outlook, By Tissue Engineering (2021-2030) ($MN)
  • Table 43 North America Human Embryonic Stem Cells Market Outlook, By Toxicology Testing (2021-2030) ($MN)
  • Table 44 North America Human Embryonic Stem Cells Market Outlook, By Blood Disease Treatment (2021-2030) ($MN)
  • Table 45 North America Human Embryonic Stem Cells Market Outlook, By Treatment of Cardiovascular Disease (2021-2030) ($MN)
  • Table 46 North America Human Embryonic Stem Cells Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 47 Europe Human Embryonic Stem Cells Market Outlook, By Country (2021-2030) ($MN)
  • Table 48 Europe Human Embryonic Stem Cells Market Outlook, By Type (2021-2030) ($MN)
  • Table 49 Europe Human Embryonic Stem Cells Market Outlook, By Totipotent Stem Cells (2021-2030) ($MN)
  • Table 50 Europe Human Embryonic Stem Cells Market Outlook, By Pluripotent Stem Cells (2021-2030) ($MN)
  • Table 51 Europe Human Embryonic Stem Cells Market Outlook, By Multipotent Stem Cells (2021-2030) ($MN)
  • Table 52 Europe Human Embryonic Stem Cells Market Outlook, By Oligopotent Stem Cells (2021-2030) ($MN)
  • Table 53 Europe Human Embryonic Stem Cells Market Outlook, By Unipotent Stem Cells (2021-2030) ($MN)
  • Table 54 Europe Human Embryonic Stem Cells Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 55 Europe Human Embryonic Stem Cells Market Outlook, By Source (2021-2030) ($MN)
  • Table 56 Europe Human Embryonic Stem Cells Market Outlook, By Bone Marrow (2021-2030) ($MN)
  • Table 57 Europe Human Embryonic Stem Cells Market Outlook, By Adult Body Tissues (2021-2030) ($MN)
  • Table 58 Europe Human Embryonic Stem Cells Market Outlook, By Embryonic Tissues (2021-2030) ($MN)
  • Table 59 Europe Human Embryonic Stem Cells Market Outlook, By Fetal tissues (2021-2030) ($MN)
  • Table 60 Europe Human Embryonic Stem Cells Market Outlook, By Differentiated Somatic Cells (2021-2030) ($MN)
  • Table 61 Europe Human Embryonic Stem Cells Market Outlook, By Other Sources (2021-2030) ($MN)
  • Table 62 Europe Human Embryonic Stem Cells Market Outlook, By Application (2021-2030) ($MN)
  • Table 63 Europe Human Embryonic Stem Cells Market Outlook, By Stem Cell Biology Research (2021-2030) ($MN)
  • Table 64 Europe Human Embryonic Stem Cells Market Outlook, By Regenerative Medicine (2021-2030) ($MN)
  • Table 65 Europe Human Embryonic Stem Cells Market Outlook, By Tissue Engineering (2021-2030) ($MN)
  • Table 66 Europe Human Embryonic Stem Cells Market Outlook, By Toxicology Testing (2021-2030) ($MN)
  • Table 67 Europe Human Embryonic Stem Cells Market Outlook, By Blood Disease Treatment (2021-2030) ($MN)
  • Table 68 Europe Human Embryonic Stem Cells Market Outlook, By Treatment of Cardiovascular Disease (2021-2030) ($MN)
  • Table 69 Europe Human Embryonic Stem Cells Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 70 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Country (2021-2030) ($MN)
  • Table 71 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Type (2021-2030) ($MN)
  • Table 72 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Totipotent Stem Cells (2021-2030) ($MN)
  • Table 73 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Pluripotent Stem Cells (2021-2030) ($MN)
  • Table 74 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Multipotent Stem Cells (2021-2030) ($MN)
  • Table 75 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Oligopotent Stem Cells (2021-2030) ($MN)
  • Table 76 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Unipotent Stem Cells (2021-2030) ($MN)
  • Table 77 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 78 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Source (2021-2030) ($MN)
  • Table 79 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Bone Marrow (2021-2030) ($MN)
  • Table 80 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Adult Body Tissues (2021-2030) ($MN)
  • Table 81 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Embryonic Tissues (2021-2030) ($MN)
  • Table 82 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Fetal tissues (2021-2030) ($MN)
  • Table 83 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Differentiated Somatic Cells (2021-2030) ($MN)
  • Table 84 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Other Sources (2021-2030) ($MN)
  • Table 85 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Application (2021-2030) ($MN)
  • Table 86 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Stem Cell Biology Research (2021-2030) ($MN)
  • Table 87 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Regenerative Medicine (2021-2030) ($MN)
  • Table 88 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Tissue Engineering (2021-2030) ($MN)
  • Table 89 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Toxicology Testing (2021-2030) ($MN)
  • Table 90 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Blood Disease Treatment (2021-2030) ($MN)
  • Table 91 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Treatment of Cardiovascular Disease (2021-2030) ($MN)
  • Table 92 Asia Pacific Human Embryonic Stem Cells Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 93 South America Human Embryonic Stem Cells Market Outlook, By Country (2021-2030) ($MN)
  • Table 94 South America Human Embryonic Stem Cells Market Outlook, By Type (2021-2030) ($MN)
  • Table 95 South America Human Embryonic Stem Cells Market Outlook, By Totipotent Stem Cells (2021-2030) ($MN)
  • Table 96 South America Human Embryonic Stem Cells Market Outlook, By Pluripotent Stem Cells (2021-2030) ($MN)
  • Table 97 South America Human Embryonic Stem Cells Market Outlook, By Multipotent Stem Cells (2021-2030) ($MN)
  • Table 98 South America Human Embryonic Stem Cells Market Outlook, By Oligopotent Stem Cells (2021-2030) ($MN)
  • Table 99 South America Human Embryonic Stem Cells Market Outlook, By Unipotent Stem Cells (2021-2030) ($MN)
  • Table 100 South America Human Embryonic Stem Cells Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 101 South America Human Embryonic Stem Cells Market Outlook, By Source (2021-2030) ($MN)
  • Table 102 South America Human Embryonic Stem Cells Market Outlook, By Bone Marrow (2021-2030) ($MN)
  • Table 103 South America Human Embryonic Stem Cells Market Outlook, By Adult Body Tissues (2021-2030) ($MN)
  • Table 104 South America Human Embryonic Stem Cells Market Outlook, By Embryonic Tissues (2021-2030) ($MN)
  • Table 105 South America Human Embryonic Stem Cells Market Outlook, By Fetal tissues (2021-2030) ($MN)
  • Table 106 South America Human Embryonic Stem Cells Market Outlook, By Differentiated Somatic Cells (2021-2030) ($MN)
  • Table 107 South America Human Embryonic Stem Cells Market Outlook, By Other Sources (2021-2030) ($MN)
  • Table 108 South America Human Embryonic Stem Cells Market Outlook, By Application (2021-2030) ($MN)
  • Table 109 South America Human Embryonic Stem Cells Market Outlook, By Stem Cell Biology Research (2021-2030) ($MN)
  • Table 110 South America Human Embryonic Stem Cells Market Outlook, By Regenerative Medicine (2021-2030) ($MN)
  • Table 111 South America Human Embryonic Stem Cells Market Outlook, By Tissue Engineering (2021-2030) ($MN)
  • Table 112 South America Human Embryonic Stem Cells Market Outlook, By Toxicology Testing (2021-2030) ($MN)
  • Table 113 South America Human Embryonic Stem Cells Market Outlook, By Blood Disease Treatment (2021-2030) ($MN)
  • Table 114 South America Human Embryonic Stem Cells Market Outlook, By Treatment of Cardiovascular Disease (2021-2030) ($MN)
  • Table 115 South America Human Embryonic Stem Cells Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 116 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Country (2021-2030) ($MN)
  • Table 117 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Type (2021-2030) ($MN)
  • Table 118 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Totipotent Stem Cells (2021-2030) ($MN)
  • Table 119 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Pluripotent Stem Cells (2021-2030) ($MN)
  • Table 120 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Multipotent Stem Cells (2021-2030) ($MN)
  • Table 121 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Oligopotent Stem Cells (2021-2030) ($MN)
  • Table 122 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Unipotent Stem Cells (2021-2030) ($MN)
  • Table 123 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 124 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Source (2021-2030) ($MN)
  • Table 125 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Bone Marrow (2021-2030) ($MN)
  • Table 126 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Adult Body Tissues (2021-2030) ($MN)
  • Table 127 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Embryonic Tissues (2021-2030) ($MN)
  • Table 128 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Fetal tissues (2021-2030) ($MN)
  • Table 129 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Differentiated Somatic Cells (2021-2030) ($MN)
  • Table 130 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Other Sources (2021-2030) ($MN)
  • Table 131 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Application (2021-2030) ($MN)
  • Table 132 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Stem Cell Biology Research (2021-2030) ($MN)
  • Table 133 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Regenerative Medicine (2021-2030) ($MN)
  • Table 134 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Tissue Engineering (2021-2030) ($MN)
  • Table 135 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Toxicology Testing (2021-2030) ($MN)
  • Table 136 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Blood Disease Treatment (2021-2030) ($MN)
  • Table 137 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Treatment of Cardiovascular Disease (2021-2030) ($MN)
  • Table 138 Middle East & Africa Human Embryonic Stem Cells Market Outlook, By Other Applications (2021-2030) ($MN)
目次
Product Code: SMRC24055

According to Stratistics MRC, the Global Human Embryonic Stem Cells Market is accounted for $1.8 billion in 2023 and is expected to reach $3.8 billion by 2030 growing at a CAGR of 11.2% during the forecast period. The inner cell mass of a human embryo during the blastocyst stage, usually 5-7 days after conception, is when human embryonic stem cells, a kind of pluripotent stem cell, are generated. The amazing capacity of these cells to develop into almost any form of cell in the human body is well recognized. They have a tremendous potential for application in regenerative medicine and research in addition to playing a critical function in early human development. It is crucial to ensure the efficacy and security of human embryonic stem-based therapeutics, to produce and deploy them, rigorous quality control procedures and safety evaluations are essential.

According to the article from DVC Stem published in August 2022, it was observed that the goal of stem cell therapy for Parkinson's disease is to replace destroyed brain cells with healthy, undifferentiated stem cells.

Market Dynamics:

Driver:

Growing technological advancements

The market for human embryonic stem cells has greatly benefited from technological improvements. With these developments, working with these cells has substantially improved in terms of effectiveness, safety, and usability, making them a more attractive alternative for research and possible therapeutic applications. Researchers can more accurately replicate the natural milieu of cells in the human body thanks to the development of three-dimensional (3D) culture models. As a result, human embryonic stem cells differentiation into certain cell types for regenerative therapy is improved. With the help of innovations like CRISPR-Cas9, the hESC genome may now be precisely edited, revolutionizing the field of gene editing. Hence all the above factors boost the market growth.

Restraint:

Concerns about the ethics of using embryonic stem cells

Studies looking into the therapeutic potential of embryonic stem cells (ESC) are linked to a number of moral dilemmas including the killing of human embryos. Lack of appropriate government laws that specify what can be supported in the development of therapies using embryo-based stem cells may eventually limit the market's growth to some extent. Federal laws are further necessary due to the complexity of the legislation in this field so that researchers, scientists, and pharmaceutical firms can develop ESC treatment and accelerate its commercialization.

Opportunity:

Rising incidence of chronic diseases

There is a high demand for efficient therapies due to the rising prevalence of chronic diseases including diabetes, cardiovascular disease, neurological disorders, and autoimmune ailments. These diseases, which frequently include permanent tissue damage, may be treated using human embryonic stem cells -based therapy. Tissue deterioration and organ dysfunction are frequently seen in patients with chronic illnesses and are a useful resource for tackling the long-term effects of chronic illnesses because regenerative medicine techniques use them to repair, replace, or regenerate damaged tissues and organs. To determine the safety and effectiveness of human embryonic stem-based treatments for particular chronic conditions, clinical studies have been started.

Threat:

Tendency of immune rejection

Immune rejection may cause human embryonic stem cells-derived cell treatments to fail. Transplanted cells may be attacked and killed if the immune system of the recipient recognizes them as alien, making the therapy useless and it may limit the long-term advantages of therapy based on human embryonic stem cells. Even if the initial engraftment is effective, the persistent immune response may cause the transplanted cells to gradually disappear, decreasing the therapeutic effect's longevity thus hampering the market growth.

COVID-19 Impact

The pandemic interfered with laboratory research projects, particularly stem cell projects. The development of human embryonic stem cells research and clinical trials was hampered by the temporary closure or reduction of activities at several research organizations. Moreover, the progress of these trials was slowed down by site closures, challenges with patient recruiting, and safety worries and made safety and efficacy of medical research and therapy development even more important. This might result in human embryonic stem cells -based medicines receiving more thorough safety evaluations which hinder the market growth.

The totipotent stem cells segment is expected to be the largest during the forecast period

The totipotent stem cells segment is estimated to have a lucrative growth, as these are special kind of stem cell and all cell types in the human body, including extraembryonic and embryonic tissues, may be formed from these cells, which is extraordinary. They vary from pluripotent stem cells, though, in that the latter can develop into all bodily cell types except for extraembryonic tissues. Understanding how totipotent stem cells develop into distinct cell types can be aided by research employing these cells.

The stem cell biology research segment is expected to have the highest CAGR during the forecast period

The stem cell biology research segment is anticipated to witness the highest CAGR growth during the forecast period, as these are living things that can develop into many kinds of cells. Various stem cell types are also employed in medical treatments. Numerous biopharmaceutical firms have recently conducted substantial research into these compounds, which have numerous uses at the clinical stage for a variety of disorders, including cancer and neurological ailments. Due to the growing frequency of disorders like Parkinson's disease, cancer, and others, stem cell biology research will see improved growth. The market under study is thus anticipated to see a significant growth rate throughout the projected period as a result of these reasons.

Region with largest share:

North America is projected to hold the largest market share during the forecast period owing to the growing government emphasis on drug discovery, healthcare investment, and advanced infrastructure for the development of technologies in drug discovery, as well as expanding development strategies used by several business verticals in the area. Furthermore, it is predicted that strict regulatory rules for medication research and related clinical studies would spur the market. The launch of biological and bio similar drugs by biopharmaceutical manufacturers in the US is another factor that is anticipated to fuel the market's expansion.

Region with highest CAGR:

Europe is projected to have the highest CAGR over the forecast period, owing to stringent laws governing the use of human embryonic stem cells for both research and therapy. The creation and endorsement of stem cell-based medicines are regulated by national regulatory organizations and the European Medicines Agency (EMA). For instance, in Europe, human embryonic stem cells -based clinical studies have been carried out or are now being done for a range of illnesses, including spinal cord injury, heart disease, and degenerative diseases. The purpose of these trials is to assess the efficacy and safety of stem cell-based treatments. To advance human embryonic stem cells research and turn it into practical applications, partnerships between academic institutions, biotech firms, and healthcare facilities are typical in this region which encourages the market.

Key players in the market:

Some of the key players profiled in the Human Embryonic Stem Cells Market include: PeproTech Inc., Astellas Pharma Inc., Merck KGaA, Lineage Cell Therapeutics Inc., PromoCell GmbH, Thermo Fisher Scientific, ViaCyte, Inc., Takara Bio Inc., STEMCELL Technologies Inc, Cell Cure Neurosciences LTD, CellGenix GmbH, ESI BIO, Lonza, Kite Pharma, Cynata, Sumanas, Inc., LifeCell, International Stem Cell Corporation, Genea BioCells and Geron

Key Developments:

In October 2023, Astellas Pharma Inc. and BioLabs Global, Incand Mitsui Fudosan, announced that they have agreed on a tri-party memorandum of understanding to enhance the life science ecosystem in Tsukuba and Kashiwa-no-ha, Japan, world-renowned science hubs.

In October 2023, Merck launches new collaboration with United Nations-Guided Global Initiative on ageing to support carers; new training course provides critical skills for unpaid family carers and coincides with European Carers Day and Family Caregiver awareness month in the U.S.

In September 2023, Thermo Fisher Scientific expands St. Louis manufacturing for complex biologic treatments for diseases ranging from cancers to auto immune conditions to rare genetic disorders.

In September 2023, Thermo Fisher Scientific Inc. the world leader in serving science, and the National Minority Quality Forum (NMQF), an independent not-for-profit research and education organization, announced a collaboration to help bring clinical research to historically underserved patient populations through NMQF's Alliance for Representative Clinical Trials (ARC).

Types Covered:

  • Totipotent Stem Cells
  • Pluripotent Stem Cells
  • Multipotent Stem Cells
  • Oligopotent Stem Cells
  • Unipotent Stem Cells
  • Other Types

Sources Covered:

  • Bone Marrow
  • Adult Body Tissues
  • Embryonic Tissues
  • Fetal tissues
  • Differentiated Somatic Cells
  • Other Sources

Applications Covered:

  • Stem Cell Biology Research
  • Regenerative Medicine
  • Tissue Engineering
  • Toxicology Testing
  • Blood Disease Treatment
  • Treatment of Cardiovascular Disease
  • Other Applications

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Human Embryonic Stem Cells Market, By Type

  • 5.1 Introduction
  • 5.2 Totipotent Stem Cells
  • 5.3 Pluripotent Stem Cells
  • 5.4 Multipotent Stem Cells
  • 5.5 Oligopotent Stem Cells
  • 5.6 Unipotent Stem Cells
  • 5.7 Other Types

6 Global Human Embryonic Stem Cells Market, By Source

  • 6.1 Introduction
  • 6.2 Bone Marrow
  • 6.3 Adult Body Tissues
  • 6.4 Embryonic Tissues
  • 6.5 Fetal tissues
  • 6.6 Differentiated Somatic Cells
  • 6.7 Other Sources

7 Global Human Embryonic Stem Cells Market, By Application

  • 7.1 Introduction
  • 7.2 Stem Cell Biology Research
  • 7.3 Regenerative Medicine
  • 7.4 Tissue Engineering
  • 7.5 Toxicology Testing
  • 7.6 Blood Disease Treatment
  • 7.7 Treatment of Cardiovascular Disease
  • 7.8 Other Applications

8 Global Human Embryonic Stem Cells Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 PeproTech Inc.
  • 10.2 Astellas Pharma Inc.
  • 10.3 Merck KGaA
  • 10.4 Lineage Cell Therapeutics Inc.
  • 10.5 PromoCell GmbH
  • 10.6 Thermo Fisher Scientific
  • 10.7 ViaCyte, Inc.
  • 10.8 Takara Bio Inc.
  • 10.9 STEMCELL Technologies Inc
  • 10.10 Cell Cure Neurosciences LTD
  • 10.11 CellGenix GmbH
  • 10.12 ESI BIO
  • 10.13 Lonza
  • 10.14 Kite Pharma
  • 10.15 Cynata
  • 10.16 Sumanas, Inc.
  • 10.17 LifeCell
  • 10.18 International Stem Cell Corporation
  • 10.19 Genea BioCells
  • 10.20 Geron